Cancer Pain Treated by Miao Medicine Crossbow Medicine Needle Therapy Combined with Oxycodone Hydrochloride Extended-release Tablets： A Randomized Controlled Trial of 67 Cases

CHEN Hui; WU Wenyu; PAN Dingju; SHUI Huili; WANG Dingxue; YANG Zhu; LUO Li; YANG Bing; TANG Dongxin

doi:10.13288/j.11-2166/r.2022.24.009

您当前的位置：

首页 >

文章列表页 >

Cancer Pain Treated by Miao Medicine Crossbow Medicine Needle Therapy Combined with Oxycodone Hydrochloride Extended-release Tablets： A Randomized Controlled Trial of 67 Cases

更新时间：2022-12-13

- Cancer Pain Treated by Miao Medicine Crossbow Medicine Needle Therapy Combined with Oxycodone Hydrochloride Extended-release Tablets： A Randomized Controlled Trial of 67 Cases
- Journal of Traditional Chinese Medicine Vol. 63, Issue 24, Pages: 2346-2352(2022)
- 作者机构：
  
  1.贵州中医药大学，贵州省贵阳市南明区市东路50号，550002
  2.贵州中医药大学第一附属医院
  3.贵航贵阳医院
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2022.24.009
  CLC：
- Received：05 July 2022，
  
  Revised：2022-09-30，
  
  Published：17 December 2022
- 稿件说明：
移动端阅览
陈慧,吴文宇,潘定举等.苗医弩药针疗法联合盐酸羟考酮缓释片治疗癌性疼痛67例随机对照研究[J].中医杂志,2022,63(24):2346-2352.

CHEN Hui,WU Wenyu,PAN Dingju,et al.Cancer Pain Treated by Miao Medicine Crossbow Medicine Needle Therapy Combined with Oxycodone Hydrochloride Extended-release Tablets： A Randomized Controlled Trial of 67 Cases[J].Journal of Traditional Chinese Medicine,2022,63(24):2346-2352.
陈慧,吴文宇,潘定举等.苗医弩药针疗法联合盐酸羟考酮缓释片治疗癌性疼痛67例随机对照研究[J].中医杂志,2022,63(24):2346-2352. DOI： 10.13288/j.11-2166/r.2022.24.009.

CHEN Hui,WU Wenyu,PAN Dingju,et al.Cancer Pain Treated by Miao Medicine Crossbow Medicine Needle Therapy Combined with Oxycodone Hydrochloride Extended-release Tablets： A Randomized Controlled Trial of 67 Cases[J].Journal of Traditional Chinese Medicine,2022,63(24):2346-2352. DOI： 10.13288/j.11-2166/r.2022.24.009.

摘要

目的

探讨苗医弩药针疗法联合盐酸羟考酮缓释片在癌性疼痛中的应用效果及安全性。

方法

采用区组随机方法将144例癌性疼痛患者分为治疗组和对照组各72例。对照组患者给予盐酸羟考酮缓释片口服，每12 h 1次；治疗组在对照组基础上，加用苗医弩药针疗法，隔日1次。两组均治疗14天。比较两组治疗患者治疗前后疼痛数字评分（NRS）评分（包括最剧烈、最轻微、平均及目前疼痛）、简明疼痛评估量表（BPI）评分（包括BPI疼痛强度评分、BPI疼痛影响情况评分及BPI总评分）、日爆发痛次数、盐酸羟考酮片日使用量、免疫指标［包括CD3

T淋巴细胞（CD3

）、CD4

T淋巴细胞（CD4

）、CD8

T淋巴细胞（CD8

）和CD4

/CD8

］，评价临床疗效并计算治疗过程中不良反应发生率。

结果

治疗组67例、对照组64例完成观察。治疗组总有效率76.12%，显著高于对照组的40.63%（

＜0.01）。两组患者治疗后最剧烈、最轻微、平均及目前疼痛NRS评分均较治疗前显著降低（

＜0.01）；治疗后治疗组患者最剧烈、最轻微、平均及目前疼痛NRS评分均较对照组低（

＜0.01），且治疗组各指标治疗前后差值均显著大于对照组（

＜0.01）。治疗后，两组患者BPI总评分、BPI疼痛强度评分及BPI疼痛影响情况评分均较治疗前明显降低（

＜0.01）；治疗后治疗组患者BPI总评分、BPI疼痛强度评分、BPI疼痛影响情况评分均较对照组低（

＜0.01），且治疗组各指标治疗前后差值均大于对照组（

＜0.01）。治疗后两组患者盐酸羟考酮片日使用量均较治疗前增加（

＜0.01），两组治疗前后差值比较，对照组增加幅度显著高于治疗组（

＜0.05）。治疗后两组患者日爆发痛次数均较治疗前明显减少（

＜0.01）；治疗后治疗组患者日爆发痛次数较对照组少（

＜0.01），且治疗组治疗前后差值显著大于对照组（

＜0.05）。治疗后治疗组患者CD3

含量较治疗前升高（

＜0.05），其他免疫指标治疗前后及两组治疗后比较，差异均无统计学意义（

＞0.05）。治疗组不良反应发生率为15.28%，对照组为27.78%，两组比较差异无统计学意义（

＞0.05）。

结论

苗医弩药针疗法联合盐酸羟考酮缓释片治疗癌性疼痛疗效确切，且在增强止痛疗效、提高生活质量方面优于单纯盐酸羟考酮缓释片治疗。

Abstract

Objective

To investigate the effectiveness and safety of Miao Medicine crossbow medicine needle therapy combined with oxycodone hydrochloride extended-release tablets in treatment of cancer pain.

Methods

Totally 144 patients with cancer pain were divided into treatment group and control group using block randomization method， with 72 patients in each group. Control group was given oxycodone hydrochloride extended-release tablets orally， once every 12 hours. Treatment group was additionally given Miao Medicine crossbow medicine needle therapy， once every other day. Both groups were treated for 14 days. The numeric rating scale （NRS） scores including the worst， least， present and average pain score， the Brief Pain Inventory （BPI） scores including the pain intensity， impact and total score， the daily frequency of pain， the daily consumption of oxycodone hydrochloride extended-release tablets， and immune indicators including CD3

T lymphocytes （CD3

）， CD4

T lymphocytes （CD4

）， CD8

T lymphocytes （CD8

） and CD4

/CD8

were evaluated before and after treatment to evaluate the clinical efficacy， and the incidence of adverse reactions during treatment was calculated.

Results

Totally， 67 cases in the treatment group and 64 cases in the control group completed the trial. The total effective rate of the treatment group was 76.12%， which was significantly higher than 40.63% of the control group （

＜0.01）. The NRS scores of the worst， least， average and present pain significantly decreased in both groups after treatment （

＜0.01）， and were significantly lower in the control group （

＜0.01）； the changes before and after treatment of NRS scores were significantly larger （

＜0.01）. The BPI total score， intensity score and impact score of two groups significantly decreased after treatment （

＜0.01）， and were significantly lower in the control group （

＜0.01）； the changes before and after treatment of the BPI scores were significantly larger in the treatment group （

＜0.01）. The daily consumption of oxycodone hydrochloride tablets in both groups significantly increased after treatment （

＜0.01）， and the change before and after treatment was significantly larger in the control group （

＜0.05）. The daily frequency of pain was significantly reduced in both groups after treatment （

＜0.01）， and was lower in the treatment group （

＜0.01） with more change before and after treatment （

＜0.05）. The CD3

content in the treatment group was significantly higher after treatment （

＜0.05）， with no statistical significantly differences in other immune indicators before and after treatment （

＞0.05）. The incidence of adverse reactions was 15.28% in the treatment group and 27.78% in the control group， with no statistical significance between the two groups （

＞0.05）.

Conclusion

Miao Medicine crossbow medicine needle therapy combined with oxycodone hydrochloride extended-release tablets has definite curative effect in the treatment of cancer pain， and is superior to oxycodone hydrochloride extended-release tablets alone in enhancing analgesic efficacy and improving quality of life.

关键词

Keywords

references

中国抗癌协会癌症康复与姑息治疗专业委员会难治性癌痛学组，中华医学会疼痛学分会癌痛学组 . 癌性爆发痛专家共识（2019年版）［J］. 中国肿瘤临床， 2019 ， 46 （ 6 ）： 267 - 271 .

WANG Y ， XING L . Role of oxycodone hydrochloride in treating radiotherapy-related pain ［J］. Pain Res Manag ， 2020 ， 20 （ 20 ）： 756 - 762 .

腾红丽，韦英才 . 民族医特色诊疗技术规范［M］. 北京：中国医药科技出版社， 2015 ： 42 - 47 .

陈果，杨柱，唐东昕 . 民族医药肿瘤特色外治疗法概述［J］. 中华中医药杂志， 2021 ， 36 （ 4 ）： 2225 - 2228 .

税会利，杨柱，崔瑾，等 . 苗医与中医治疗癌性疼痛的异同［J］. 中医杂志， 2017 ， 58 （ 24 ）： 2158 - 2160 .

石远凯，孙燕 . 临床肿瘤内科手册［M］. 6版 . 北京：人民卫生出版社， 2015 ： 2 - 5 .

中华人民共和国国家卫生健康委员会 . 癌症疼痛诊疗规范（2018年版）［J］. 临床肿瘤学杂志， 2018 ， 23 （ 10 ）： 937 - 944 .

FARRAR JT ， YOUNG JP JR ， LAMOREAUX L ， et al . Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale ［J］. Pain ， 2001 ， 94 （ 2 ）： 149 - 158 .

YILDIZ CELTEK N ， SUREN M ， DEMIR O ， et al . Karnofsky Performance Scale validity and reliability of Tur-kish palliative cancer patients ［J］. Turk J Med Sci ， 2019 ， 49 （ 3 ）： 894 - 898 .

CLEELAND CS ， RYAN KM . Pain assessment： global use of the Brief Pain Inventory ［J］. Ann Acad Med Singap ， 1994 ， 23 （ 2 ）： 129 - 138 .

周际昌 . 实用肿瘤内科学［M］. 北京：人民卫生出版社， 1999 ： 187 - 189 .

DALAL S ， BRUERA E . Pain management for patients with advanced cancer in the opioid epidemic era ［J］. Am Soc Clin Oncol Educ Book ， 2019 ， 17 （ 39 ）： 24 - 35 .

MERCADANTE S ， ARCURI E ， SANTONI A . Opioid-induced tolerance and hyperalgesia ［J］. CNS Drugs ， 2019 ， 33 （ 10 ）： 943 - 955 .

DAI J ， TENG L ， ZHAO L ， et al . The combined analgesic effect of pregabalin and morphine in the treatment of pancreatic cancer pain， a retrospective study ［J］. Cancer Med ， 2021 ， 10 （ 5 ）： 1738 - 1744 .

MATHEW B ， LENNON FE ， SIEGLER J ， et al . The novel role of the mu opioid receptor in lung cancer progression： a laboratory investigation ［J］. Anesth Analg ， 2011 ， 112 （ 3 ）： 558 - 567 .

田兴秀 . 中国苗族医学［M］. 贵阳：贵州科技出版社， 2013 ： 267 - 299 ．

杜江 . 苗医治疗学的方法和特点［J］. 中华中医药杂志， 2007 ， 22 （ 7 ）： 483 - 485 .

陈亦乐，孙明子，肖淦辰，等 . 改良型苗医弩药针疗法治疗膝骨性关节炎技术规范研究［J］. 亚太传统医药， 2015 ， 11 （ 4 ）： 19 - 20 .

李朝斗 . 苗族医药珍宝：弩药与糖药针［J］. 贵州医药， 1988 ， 12 （ 2 ）： 90 - 98 .

税会利 . 苗医弩药针疗法干预癌性疼痛的临床研究及对比论述苗医理论与中医理论防治癌性疼痛的指导作用［D］. 贵阳：贵州中医药大学， 2019 .

ALMOUAALAMY N ， ALHARBI ZM ， ALDOSARI FM ， et al . The practice of pain assessment and management in a tertiary oncology center ［J］. Cureus ， 2021 ， 13 （ 10 ）： e18837 .

TERREN I ， ORRANTIA A ， VITALLE J ， et al . NK cell metabolism and tumor microenvironment ［J］. Front Immunol ， 2019 ， 24 （ 10 ）： 2278 .

SINGH A ， DEES S ， GREWAL IS . Overcoming the challenges associated with CD3 + T-cell redirection in cancer ［J］. Br J Cancer ， 2021 ， 124 （ 6 ）： 1037 - 1048 .

BORST J ， AHRENDS T ， BABALA N ， et al . CD4 + T cell help in cancer immunology and immunotherapy ［J］. Nat Rev Immunol ， 2018 ， 18 （ 10 ）： 635 - 647 .

FARHOOD B ， NAJAFI M ， MORTEZAEE K . CD8 + cytotoxic T lymphocytes in cancer immunotherapy： A review ［J］. J Cell Physiol ， 2019 ， 234 （ 6 ）： 8509 - 8521 .

王伟宁 . 氢吗啡酮鞘内自控镇痛治疗难治性癌痛的临床研究及对患者免疫状态的影响［D］. 青岛：青岛大学， 2017 .

徐春华，于力克，张宇 . 化疗对中晚期非小细胞肺癌患者淋巴细胞亚群的影响［J］. 实用肿瘤杂志， 2011 ， 26 （ 2 ）： 150 - 153 .

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Xingeng No.Ⅱ Granules （心梗2号颗粒剂） on Left Ventricular Remodeling in Patients of ST-Segment Elevation Myocardial Infarction with Qi Deficiency and Blood Stasis Syndrome after PCI：An Open-Labbled Randomized-Controlled Trial

Qingre Chushi Decoction （清热除湿汤） in Treating Herpes Zoster with Constraint Heat in the Liver Channel Syndrome：A Multicenter， Randomized Controlled Trial

Current Situation and Methodological Reflections on Blinding Assessment in Randomised Controlled Trials of Acupuncture

Clinical Efficacy of Yiqi Yangyin Jiedu Huayu Formula （益气养阴解毒化瘀方） Modifications Combined with Western Medicine in the Treatment of Minimal Hepatic Encephalopathy based on the Stroop Test

External Application of Xiaozheng Zhitong Gel （消癥止痛凝胶） in the Treatment of Pain from Bone Metastasis：A Randomized Controlled Trial

Related Author

YANG Chunkun

ZHU Qinwei

PAN Qingquan

LI Jun

LIU Zhiyong

QIN Wanli

MA Tengfei

ZHAO Huizhong

Related Institution

Affiliated Hospital of Shandong University of Traditional Chinese Medicine

Weifan Hospital of Traditional Chinese Medicine，Shangdong Province

Guang'anmen Hospital，China Academy of Chinese Medical Sciences

Beijing Hospital of Traditional Chinese Medicine，Capital Medical University

Air Force Medical Center，People's Liberation Army

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰